Arham Drugs And Chemicals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 24-10-2024
- Paid Up Capital ₹ 10.44 Cr
as on 24-10-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.71 Cr
as on 24-10-2024
- Satisfied Charges ₹ 12.74 Cr
as on 24-10-2024
- Revenue -48.03%
(FY 2023)
- Profit -87.25%
(FY 2023)
- Ebitda -4.62%
(FY 2023)
- Net Worth 4.16%
(FY 2023)
- Total Assets -2.29%
(FY 2023)
About Arham Drugs And Chemicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 10.44 Cr.
The company currently has active open charges totaling ₹16.71 Cr. The company has closed loans amounting to ₹12.74 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhavin Shah, Rajnikant Shah, and Hetal Shah serve as directors at the Company.
- CIN/LLPIN
U24231MH2010PTC203991
- Company No.
203991
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jun 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Arham Drugs And Chemicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnikant Shah  | Director | 07-Sep-2011 | Current |
| Bhavin Shah | Director | 10-Jun-2010 | Current |
| Hetal Shah | Director | 01-Jun-2014 | Current |
Financial Performance of Arham Drugs And Chemicals.
Arham Drugs And Chemicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48.03% decrease. The company also saw a substantial fall in profitability, with a 87.25% decrease in profit. The company's net worth moved up by a moderate rise of 4.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arham Drugs And Chemicals?
In 2023, Arham Drugs And Chemicals had a promoter holding of 99.92% and a public holding of 0.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Heat Nutraceuticals Private LimitedActive 5 years 1 monthBhavin Shah and Hetal Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 20 Jul 2022 | ₹16.71 Cr | Open |
Others Creation Date: 05 Oct 2019 | ₹5.54 Cr | Satisfied |
Abhyudaya Co-Operative Bank Limited Creation Date: 18 May 2018 | ₹5.00 M | Satisfied |
How Many Employees Work at Arham Drugs And Chemicals?
Unlock and access historical data on people associated with Arham Drugs And Chemicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arham Drugs And Chemicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arham Drugs And Chemicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
